1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. PREVAILING INCIDENCE OF HEMATOLOGIC DISEASES
3.1.2. ADVANCEMENT IN TECHNOLOGIES OF APHERESIS TECHNIQUE
3.1.3. GROWING GERIATRIC POPULATION
3.2. KEY RESTRAINTS
3.2.1. RISK OF BLOOD CONTAMINATION WHILE CONDUCTING TRANSFUSIONS
3.2.2. HIGH COST OF INVESTMENT ASSOCIATED WITH APHERESIS PROCEDURES
3.2.3. LACK OF SKILLED PROFESSIONALS IN DEVELOPING AND UNDERDEVELOPED COUNTRIES

4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON APHERESIS MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRY
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE

5. MARKET BY PROCEDURE
5.1. PLASMAPHERESIS
5.2. PLATELETPHERESIS
5.3. LEUKAPHERESIS
5.4. ERYTHROCYTAPHERESIS
5.5. OTHER APHERESIS PROCEDURES

6. MARKET BY TECHNOLOGY
6.1. CENTRIFUGATION
6.2. MEMBRANE SEPARATION

7. MARKET BY PRODUCT
7.1. DISPOSABLE APHERESIS KITS
7.2. APHERESIS MACHINE

8. MARKET BY APPLICATION
8.1. HEMATOLOGICAL DISORDERS
8.2. NEUROLOGICAL DISORDERS
8.3. AUTOIMMUNE DISORDERS
8.4. RENAL DISORDERS
8.5. OTHER APPLICATIONS

9. MARKET BY END-USER
9.1. BLOOD BANKS/ BLOOD DONATION CENTERS
9.2. HOSPITALS & CLINICS
9.3. AMBULATORY SURGICAL CENTERS

10. GEOGRAPHICAL ANALYSIS
10.1. ASIA-PACIFIC
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. KEY GROWTH ENABLERS
10.1.3. KEY CHALLENGES
10.1.4. KEY PLAYERS
10.1.5. COUNTRY ANALYSIS
10.1.5.1. CHINA
10.1.5.2. JAPAN
10.1.5.3. INDIA
10.1.5.4. AUSTRALIA & NEW ZEALAND
10.1.5.5. SOUTH KOREA
10.1.5.6. INDONESIA
10.1.5.7. THAILAND
10.1.5.8. VIETNAM
10.1.5.9. REST OF ASIA-PACIFIC

11. COMPETITIVE LANDSCAPE
11.1. KEY STRATEGIC DEVELOPMENTS
11.1.1. MERGERS & ACQUISITIONS
11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
11.1.3. PARTNERSHIPS & AGREEMENTS
11.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS & DIVESTITURES
11.2. COMPANY PROFILES
11.2.1. ASAHI KASEI CORPORATION
11.2.2. BAXTER INTERNATIONAL INC
11.2.3. B BRAUN MELSUNGEN AG
11.2.4. CERUS CORPORATION
11.2.5. CYTOSORBENTS CORPORATION
11.2.6. FRESENIUS SE & CO KGAA (FRESENIUS KABI AG)
11.2.7. HAEMONETICS CORPORATION
11.2.8. HEMACARE CORPORATION
11.2.9. INFOMED
11.2.10. KANEKA CORPORATION
11.2.11. KAWASUMI LABORATORIES INC
11.2.12. MEDICAP CLINIC GMBH
11.2.13. MEDICA SPA
11.2.14. MILTENYI BIOTEC
11.2.15. TERUMO CORPORATION (TERUMO BCT)